Test Price
800 AED✅ Home Collection Available
Cystic Fibrosis Mutation Screening (CFTR – ΔF508) in UAE | 800 AED
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity for the ΔF508 mutation via targeted Sanger sequencing, the gold standard for single-mutation analysis.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary post-test telephonic clinical correlation session to interpret your results in context.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This test screens for the most common cystic fibrosis-causing mutation, CFTR ΔF508 (c.1521_1523delCTT), in the CFTR gene using gold-standard Sanger sequencing. Ideal for carrier screening, family planning, and diagnostic confirmation in suspected cases. The targeted approach ensures rapid and definitive identification of the p.Phe508del deletion.
| Feature | Our Test (CFTR ΔF508 Screen) | Closest Alternative (Full CFTR NGS Panel) |
|---|---|---|
| Precision | >99.9% sensitivity for ΔF508 | Broad detection of >200 mutations, sensitivity varies by allele |
| Methodology | Targeted Sanger Sequencing (gold standard) | Next-Generation Sequencing (NGS) |
| TAT | 7–8 days | 10–14 days |
| Cost | 800 AED | 1,200–1,800 AED |
| Clinical Focus | Carrier screening, familial ΔF508, targeted diagnosis | Comprehensive evaluation, atypical presentations |
Physician Insight & Safety Protocols
"A positive ΔF508 result provides a definitive molecular diagnosis for carrier status or cystic fibrosis, but it must be integrated with sweat chloride testing and clinical symptoms. I emphasize that a negative result does not rule out other CFTR mutations, and genetic counselling remains a cornerstone before and after testing."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Exclusion Criteria & ER Red Flags
- This test is not indicated for acute respiratory distress or meconium ileus in neonates; seek emergency care immediately.
- Recent blood transfusion (<4 weeks) may cause maternal or donor DNA contamination – reschedule collection.
- Patients unable to provide informed consent for genetic testing (per Federal Decree-Law No. 4 of 2016 on Medical Liability) or minors without legal guardian approval are ineligible.
- If experiencing severe dehydration, significant weight loss, or acute pulmonary exacerbation, prioritize urgent clinical management over elective testing.
Patient FAQ & Clinical Guidance
1. How is the CFTR ΔF508 mutation test performed and how accurate is it?
A: Our laboratory uses Sanger sequencing to specifically detect the deletion of phenylalanine at codon 508 with 99.9% diagnostic sensitivity, ensuring reliable carrier and diagnostic status identification when performed on a standard peripheral blood sample.
2. What does a positive result mean and what are the next steps?
A: A positive ΔF508 mutation report indicates either carrier status (one copy) or cystic fibrosis (two copies), and immediate referral to a clinical geneticist or pulmonologist for comprehensive counselling and further evaluations is strongly advised.
3. Can this be used for prenatal or newborn screening?
A: While peripheral blood is the primary sample, this targeted ΔF508 screen may be utilized as part of a preconception or prenatal carrier screening protocol when combined with partner testing and genetic counselling in accordance with UAE clinical standards.
UAE Regulatory & Data Privacy Adherence
Accreditation: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). All testing complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability. Methodology validated against standard clinical datasets.
Clinical & Logistical Metadata
| Test Name | Cystic Fibrosis Mutation Screening (CFTR – ΔF508) |
| Price (AED) | 800 AED |
| Turnaround Time | 7–8 days |
| Sample Type / Matrix | Peripheral blood (2–4 mL in EDTA tube) |
| Methodology Used | Targeted Sanger Sequencing |
| ICD-10-CM Code | E84.9, Z13.228 |
| LOINC Code | 21657-1 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians